DexCom trades at $74.63 per share and has stayed right on track with the overall market, gaining 8.3% over the last six ...

DexCom (NASDAQ:DXCM) underwent analysis by 6 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The table below provides a snapshot of their recent ratings, ...

DexCom stock (NASDAQ: DXCM) currently trades at $73 per share, around 55% below the highs of $163 seen in November 2021. In comparison, Insulet stock (NASDAQ: PODD) saw its stock decline 39% over the ...

The Non-Insured Health Benefits (NIHB) program establishes exemplary coverage for Dexcom’s real-time continuous glucose monitoring system – bringing game-changing technology to more First Nations and ...

First-ever automated insulin delivery with the tubeless Omnipod Insulin Management System and personal smartphone control Initially compatible with Dexcom G6 CGM, with no fingersticks* required ...

DexCom posts steady profits and global reach, while Insulet surges ahead with rapid revenue growth and a focused product line ...

MADRID--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the leader in continuous glucose monitoring (CGM), announced today the Dexcom G6 CGM System has received the CE Mark for use during pregnancy in ...